Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 12926 - 12950 of 14378 in total
CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.
Investigational
CT120 is an investigational autologous CD19/22 targeted CAR-T cell immunotherapy.
Investigational
ATI-1013 is a fully human nicotine-specific monoclonal antibody.
Investigational
BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA. It is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD).
Investigational
VCN-01 is an investigational, genetically modified human adenovirus encoding human PH20.
Investigational
Efocipegtrutide is a long-acting, monomeric peptide triple agonist.
Investigational
GX-G8 is a long-acting glucagon-like peptide 2 (GLP-2) being investigated for the treatment of short bowel syndrome.
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload.
Investigational
AP103 is a non-viral gene therapy that uses a delivery vector, HPAE (Highly Branched Poly β-Amino Ester), to deliver the correct collagen VII gene into skin cells.
Investigational
Investigational
HM15912 is a human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment.
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
Displaying drugs 12926 - 12950 of 14378 in total